![share_log](https://pubimg.futunn.com/2020011501945614bb02d723f1b.jpg?imageMogr2/thumbnail/76x76!/ignore-error/1/format/webp)
Vertex Pharmaceuticals | 10-K: FY2023 Annual Report
Vertex Pharmaceuticals | 10-K: FY2023 Annual Report
福泰製藥 | 10-K:2023財年年報
牛牛AI助理已提取核心訊息
Vertex Pharmaceuticals Incorporated (Vertex) reported a robust financial performance for the year 2023, with net product revenues climbing to $9.9 billion, an 11% increase from the $8.9 billion in 2022. This growth was primarily attributed to the strong uptake of TRIKAFTA/KAFTRIO in ex-U.S. markets and label extensions in younger age groups. Operating costs and expenses saw a significant rise to $6.0 billion, a 31% increase from the previous year, mainly due to increased research and development activities. Despite this, the company's income from operations stood at $3.8 billion, although it marked an 11% decrease from 2022. Vertex's cash reserves, including cash equivalents and marketable securities, grew to $13.7 billion, up from $10.9 billion at the end of 2022.
In terms of business development, Vertex continues to be a...Show More
Vertex Pharmaceuticals Incorporated (Vertex) reported a robust financial performance for the year 2023, with net product revenues climbing to $9.9 billion, an 11% increase from the $8.9 billion in 2022. This growth was primarily attributed to the strong uptake of TRIKAFTA/KAFTRIO in ex-U.S. markets and label extensions in younger age groups. Operating costs and expenses saw a significant rise to $6.0 billion, a 31% increase from the previous year, mainly due to increased research and development activities. Despite this, the company's income from operations stood at $3.8 billion, although it marked an 11% decrease from 2022. Vertex's cash reserves, including cash equivalents and marketable securities, grew to $13.7 billion, up from $10.9 billion at the end of 2022.
In terms of business development, Vertex continues to be a leading global biotechnology firm, focusing on creating transformative medicines for serious diseases. The company has a strong pipeline with clinical-stage programs in various therapeutic areas, including cystic fibrosis, sickle cell disease, and beta thalassemia. Vertex's TRIKAFTA/KAFTRIO was approved in the U.S. and E.U. for treating nearly three-quarters of the 92,000 people with cystic fibrosis in North America, Europe, and Australia. The company also launched CASGEVY, a gene-edited cell therapy for severe sickle cell disease and transfusion-dependent beta thalassemia, now approved in multiple regions.
Looking ahead, Vertex is preparing for the near-term launches of new products in cystic fibrosis and acute pain. The company's strategy includes advancing multiple compounds or therapies from each program into early clinical trials to select the most promising therapies for later-stage development. Vertex aims to rapidly follow its first-in-class therapies with potential best-in-class candidates to provide durable clinical and commercial success. The company's financial health and strategic initiatives position it well for continued growth and innovation in the biotechnology sector.
福泰製藥公司(Vertex)公佈了2023年的強勁財務業績,淨產品收入攀升至99億美元,較2022年的89億美元增長了11%。這一增長主要歸因於在非美國市場上TRIKAFTA/KAFTRIO的強勁銷售和年輕年齡組的擴展標籤。營業成本和費用大幅攀升至60億美元,比去年增長31%,主要是由於研究和開發活動的增加。儘管如此,公司的經營收入爲38億美元,雖然較2022年下降了11%。Vertex的現金儲備,包括現金和市場able證券,增至137億美元,而2022年底爲109億美元。
就業務發展而言,Vertex 繼續成爲全球領先的生物技術公司,專注於打造針對嚴重疾病的革命性藥物。公司在多個治療領域擁...展開全部
福泰製藥公司(Vertex)公佈了2023年的強勁財務業績,淨產品收入攀升至99億美元,較2022年的89億美元增長了11%。這一增長主要歸因於在非美國市場上TRIKAFTA/KAFTRIO的強勁銷售和年輕年齡組的擴展標籤。營業成本和費用大幅攀升至60億美元,比去年增長31%,主要是由於研究和開發活動的增加。儘管如此,公司的經營收入爲38億美元,雖然較2022年下降了11%。Vertex的現金儲備,包括現金和市場able證券,增至137億美元,而2022年底爲109億美元。
就業務發展而言,Vertex 繼續成爲全球領先的生物技術公司,專注於打造針對嚴重疾病的革命性藥物。公司在多個治療領域擁有處於臨床階段的項目,包括囊性纖維化、鐮狀細胞貧血和β地中海貧血。Vertex的TRIKAFTA/KAFTRIO已獲得美國和歐盟的批准,用於治療在北美、歐洲和澳大利亞約92,000名患有囊性纖維化的人群中近三分之三。公司還推出了CASGEVY,這是一種用於治療嚴重鐮狀細胞貧血和輸血依賴型β地中海貧血的基因編輯細胞療法,目前在多個地區獲得批准。
展望未來,Vertex正在爲囊性纖維化和急性疼痛的新產品進行近期發行的準備。公司的策略包括使每個程序中的多種化合物或療法進入早期臨床試驗,以選擇最有前途的療法進行後期開發。Vertex旨在在推出首個一類療法後迅速推出潛在的最佳類療法,以提供持久的臨床和商業成功。公司的財務狀況和戰略舉措使其在生物技術板塊的持續增長和創新方面處於有利地位。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了